Topics:

Rheumatology Network

Will You Buy In on the Next Biosimilar?

The FDA has deferred a scheduled meeting about Remsima, the infliximab biosimilar already approved in Europe and still awaiting judgment in the US. But approval of the first US biosimilar (a version of the cancer drug filgrastim) prompted warnings from two organizations concerned with rheumatic disease, including the ACR. Are you ready the next challenge to your clinical judgment?

Recent Content

Although studies of ultrasound diagnosis for gout are scarce, the authors of two reviews maintain the evidence is good that it is a useful option--and may be leading to some revisions in the way the condition is detectedl.

About 30% of rheumatologists don't pre-test patients for hepatitis B before prescribing immunosuppressant medications. These authors offer new guidance for screening.

Tech Tips: In Part I, Dr. Bhana gave advice about sorting through the barrage of clinical journal articles that rheumatologists face every month. Here, in Part II, he shows how to save and file your choices for easy access in the future.

Women who use acetaminophen or NSAIDs regularly for years appear to be at increased risk for psoriatic arthritis, data from the Nurses Health Study reveal.

(AAOS2015) Patients with inflammatory arthritis appear to be at less risk for complications from knee or hip replacement than those with osteoarthritis, a large national database reveals. But those with ankylosing spondylitis have greater risk.

(AAOS2015) Total knee replacements appear successful for the relatively young and active as well as for those over 90. For people with the most preoperative pain, however, they may not help at all.

The increased risk for venous thromoboembolism after surgery among patients with rheumatic disease appears to trace to those conditions with a clotting component. However, joint surgery in general has a high risk of this complication.

By clicking Accept, you agree to become a member of the UBM Medica Community.